The role of DNA methylation in mammalian development has been a source of controversy for some time. Methylation of DNA, which takes place on the cytosine of CpG dinucleotides, is clearly required for development, because mice lacking the maintenance methyltransferase gene Dnmt1 die early in development [1] . It is also generally agreed that the primary role of DNA methylation is to silence transcription. The protein factors involved in methylation are relatively well understood, as is the mechanism by which DNA methylation brings about transcriptional silencing. The disagreements arise, however, when it comes to the question of exactly why methylation is required. Is methylation responsible for programming tissue-specific and stage-specific gene expression? Is methylation present to limit unscheduled transcription throughout the genome? Might methylation be present solely to prevent the transcription of selfish DNA elements, which are deleterious to the host? Or is some combination of these possibilities closer to the truth? Finding the answers to these questions has proven to be quite a difficult nut to crack. A series of recent papers has brought the 'awesome power of human genetics' to bear upon these questions, providing a few surprising answers. These studies have revealed that mutations in genes encoding two of the proteins known to be involved in DNA methylation are responsible for different human genetic disorders.
ICF syndrome and DNMT3B
The ICF (immunodeficiency, centromere instability and facial anomalies) syndrome is a rare, autosomal recessive disorder in which patients suffer from immunodeficiency caused by low immunoglobulin levels and mild facial abnormalities [2] . Cultured lymphocytes from ICF patients can show decondensation of the large heterochromatic, inactive regions of chromosomes 1, 9 and 16, often resulting in the formation of abnormalities in chromosome structure. The first clue that this might involve abnormal DNA methylation came with the observation that these chromosome abnormalities are very similar to those seen when normal cells are treated with the demethylating agent 5-azacytidine [2] . This led to the finding that the sub-centromeric classical satellite DNA regions II and III, which are highly methylated in normal cells, are grossly undermethylated in ICF patients [3] .
Genetic mapping of the ICF locus to the long arm of chromosome 20 [4] narrowed the search for candidate genes, and a very likely candidate emerged when the gene encoding the de novo methyltransferase DNMT3β was found to map to this same region [5] . So far, nine different mutations in the DNMT3B gene have been identified from eight different ICF families [6] [7] [8] . Xu et al. [8] have also shown that a mutation found in one of their ICF patients produces a protein with severely impaired de novo methyltransferase activity. The spectrum of mutations thus far reported is not predicted to result in a complete lack of DNMT3β activity in any ICF patient, consistent with the fact that complete DNMT3β deficiency in mice results in prenatal lethality [7] .
DNMT3β is one of two de novo methyltransferases having overlapping functions in murine development, but is specifically required for proper methylation of centromeric minor satellite DNA in mice. This is somewhat different from the situation in human cells, in which the hypomethylation found in ICF patients is restricted to the sub-centromeric classical satellite DNA, rather than the centromeric alpha satellite DNA. Another difference between mice and humans is that, whereas classical satellite DNA from ICF patients appears mostly demethylated [3] , murine embryos lacking a functional Dnmt3b gene still show significant levels of satellite methylation [7] . The differences between DNMT3β function in mice and humans highlight the importance of the new data from ICF patients in understanding more about methylation and human disease.
So, what can the range of clinical phenotypes in ICF syndrome tell us about the role(s) of DNA methylation in humans? Given that the chromosomal abnormalities characteristic of ICF syndrome occur only in lymphocytes, might they somehow lead to the immunodeficiency that is so devastating to sufferers of this syndrome? One might expect the chromosome instability to lead directly to immunodeficiency via aneuploidy and death of lymphocytes. But the immunodeficiency in ICF syndrome is due to a general lack of immunoglobulins, and not to any cellular deficiency. Perhaps methylation is required to prevent expression of a set of genes that interfere with immunoglobulin production. Alternatively, methylation may somehow be required for efficient recombination of immunoglobulin genes in B-cell development and for the prevention of interchromosomal recombination between satellite DNA in lymphocytes. One unresolved question is why the chromosome abnormalities are visible only in lymphocytes and not in other cell types, given that the undermethylation of satellite regions II and III is apparently global in ICF syndrome [3] . DNA methylation may be required for efficient replication of satellite DNAs, and the short cell cycle of lymphocytes may not allow sufficient time for complete replication of unmethylated satellite DNA. This proposal seems somewhat counterintuitive since, in general, hypomethylation correlates with early replication. Perhaps some as yet unidentified lymphocytespecific factor binds to unmethylated satellite DNA, interfering with condensation, recombination or replication.
The mild cranio-facial abnormalities in ICF syndrome are reminiscent of those produced by chromosome aneuploidy, and thus would be consistent with aberrant gene regulation on a relatively large scale. Hypomethylation may directly lead to aberrant gene regulation in this situation, or it may act via an indirect mechanism. For example, Hansen et al. [6] suggest that the failure to properly methylate satellite II and III sequences could alter chromatin organisation of the chromosomal domains in which they reside, which in turn could affect the expression of a set of neighbouring genes important for development via so-called position effects. Xu et al. [8] suggest that methylated heterochromatin may nucleate the formation of 'silencing foci' -discrete regions of the nucleus that are rich in methylated DNA and heterochromatin-binding proteins that can silence genes in trans. This group proposes that the lack of methylation in ICF syndrome may interfere with the proper functioning of such foci, resulting in aberrant gene expression, which could lead to immunodeficiency or other developmental abnormalities.
Does the discovery of the ICF syndrome gene have any direct relevance for ICF patients? The initial impact will certainly be on prenatal diagnosis for families at risk, once more is known about the range of mutations that can give rise to ICF syndrome. Hansen et al. [6] have shown that the chromosomal phenotype can be rescued if ICF cells are fused to hamster cells, indicating that application of a wild-type copy of the DNMT3B gene can restore methylation of satellite DNA. The finding that at least one aspect of the clinical phenotype can be reversed in vitro may be a first step towards finding a treatment for ICF syndrome.
Rett syndrome and MECP2
Given that interfering with DNA methylation can give rise to immunodeficiency, centromere instability and facial abnormalities, might a similar phenotype result if a Dispatch R61
Figure 1
Disease-causing mutations in DNMT3β and MeCP2. Schematic representations of the two proteins are shown, with various protein motifs indicated. (a) Mutations identified in DNMT3β in ICF syndrome by Hansen et al. [6] are indicated in blue, those identified by Okano et al. [7] in green, and those identified by Xu et al. [8] in red. One of the families studied by Hansen et al. [6] was also studied by Okano et al. [7] . The notation 53F/S refers to a one base-pair insertion that gives rise to a frameshift after codon 53, Ins800 refers to a splicing error that results in a three amino acid insertion, and ∆737-798 refers to a splicing error resulting in a 62 amino acid deletion. Methyltransferase motifs are shown as black boxes within the catalytic domain. The grey box indicates a sequence with weak homology to motif VIII. N, amino terminus; C, carboxyl terminus. The PWWP and C-rich domains are amino-acid motifs of unknown function. (b) Mutations in MeCP2 that give rise to Rett syndrome. F/S refers to frameshifts, and a change to the letter X represents a change to a stop codon. Mutations identified by Amir et al. [9] are indicated in red, while those identified by Wan et al. [10] are indicated in orange. The various functional domains of MeCP2 are also labelled.
gene encoding a protein that binds to methylated DNA is mutated? The answer, at least in the case of one methylCpG-binding protein, is unequivocally 'no'. Mutations in the gene encoding the transcriptional repressor protein MeCP2 have been found to affect neural development in humans, taking the form of Rett syndrome [9, 10] . Patients suffering from this syndrome appear normal for the first 6-18 months of life, but then begin to lose the ability to speak or use their hands. This regression continues into autistic behaviour, ataxia, repetitive hand movements, and microcephaly, and often involves breathing abnormalities, seizures, eating problems, and growth retardation [11] . In contrast to ICF syndrome, Rett syndrome is a relatively common disorder, occurring once every 10,000-15,000 live female births [12] and is almost never seen in males. The female specificity is due to the fact that Rett syndrome is both X-linked and dominant, meaning that female patients are heterozygous whereas hemizygous males do not survive [13] .
Although Rett syndrome was initially thought to be a neurodegenerative disease, it is now recognised that the degeneration is probably due to a defect that leaves the developing brain unable to carry out the functions required of it during postnatal growth [14] . Investigations into the neuropathology of Rett syndrome have implicated abnormal levels of neurotransmitters as being potentially important for both the behavioural aspects of the disease as well as the structural brain abnormalities including microcephaly [14] . The idea that abnormal levels of one or more neuroactive transmitters are to blame is very appealing when one considers that the disease is caused by mutations in the gene encoding MeCP2. This protein has been shown to bind specifically to methylated DNA and to be a potent transcriptional repressor that is particularly abundant in the brain [15] . Might MeCP2-mediated repression be directly responsible for controlling neurotransmitter levels in brain development? This idea seems attractive, but at present it remains purely speculative.
Whereas a huge body of data has been generated on the neuropathology of Rett syndrome in humans, the identification of MECP2 as the gene responsible means that the focus can now be shifted towards experimentation in model organisms. It is already known that mice lacking a functional Mecp2 gene die during embryogenesis [16] , an observation consistent with the presumed lethality of Rett syndrome in males. Conditional knockout strategies can now be used to model Rett syndrome in mice, which will allow theories about its pathogenesis to be tested experimentally.
On average, only 50% of cells in females suffering from Rett syndrome will express the mutant form of MeCP2, assuming random X-chromosome inactivation. All Rettsyndrome-associated mutations described thus far for MeCP2 are expected to abolish its activity, because all are predicted to interfere with protein folding or structural integrity [9, 10, 17] . MeCP2 is an abundant chromosomal protein that is detectable in many somatic tissues, but no tissues other than the brain appear to be affected in Rett syndrome. Thus, MeCP2 expression is apparently not required in cells for them to give rise to a functioning liver, kidney, germ cells, and so on. Similarly, mice exhibiting a low level of chimerism for MeCP2 deficiency are viable [16] , indicating that in mice, as in humans, MeCP2-deficient cells can contribute to adult tissues. Why, then, is the brain apparently the only organ that does not function properly when some cells fail to make a functional MeCP2 protein? Perhaps the answer lies in the nature of the organ in question. Whereas hepatic function might not be noticeably impaired if a proportion of cells is not performing properly, for example, brain function is dependent upon a myriad of neuronal interconnections. Thus, if one cell is not functioning properly, it might well impair the function of several normal cells with which it interacts, effectively throwing a spanner in the workings of one or other region of the brain.
Lack of overlap
The function of DNMT3β appears to be to methylate DNA, whereas MeCP2 binds to methylated DNA; thus both proteins are involved in methylation-mediated transcriptional silencing. If this is true, then why do mutations in their respective genes give rise to diseases with completely non-overlapping symptoms? This almost certainly is because our current understanding of the in vivo functions of the DNMT3β and MeCP2 proteins, and of DNA methylation in general, is woefully incomplete. DNMT3β is only one of four potential cytosine-5 DNA methyltransferases, and MeCP2 is but one of five potential methyl-CpG-binding proteins. Thus, the potential for complexity and overlap of function is large. Linking two different components of the DNA methylation system to two very different human genetic diseases does, however, represent two large steps forward in our quest to answer that nagging question: why do we have DNA methylation, anyway?
